Ionis has announced the design for a Phase III trial of ION582, a treatment for Angelman syndrome (AS), following discussions with the FDA.

Allakos shifted focus to AK006 in 2024 after lirentelimab's failure in phase 2 trials for atopic dermatitis and CSU. Read why I'm bullish on ALLK stock.

TD Cowen analyst Yaron Werber has maintained their bullish stance on ALEC stock, giving a Buy rating on November 4. Yaron Werber has given his ...

Jupiter Neurosciences, Inc. (JUNS) is planning to raise $11 million in an initial public offering (IPO) on the week of November 11th, IPO Scoop reports. The company plans to issue 2,800,000 shares at ...

This is what Sionna’s SION‑638 aims to do. The candidate received Investigational New Drug (IND) status two years ago after which it began phase 1 trials. Another one of its candidates is SION-109, ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J200), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ...

High tissue distribution into organs of concern for invasive fungal infections.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the ...

Artificial intelligence (AI)-based risk classification improves prognostication with localized prostate cancer, according to ...

The FDA recently approved a phase 2 clinical trial to investigate the efficacy of leronlimab in patients with relapsed or ...